Validation Study Failed to Confirm an Association between Genetic Variants in the Base Excision Repair Pathway and Transplant-Related Mortality and Relapse after Hematopoietic Cell Transplantation
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Aug 01, 2016
- Source ID
- 10.1016/j.bbmt.2016.04.020
Entities
People
- Bharat Thyagarajan
- Daniel J Weisdorf
- Katharina Fleischhauer
- Katharine C Hsu
- Mary H. Horowitz
- Michael Haagenson
- Michael R Verneris
- Mukta Arora
- Stephanie J. Lee
- Stephen R. Spellman
- Tao Wang
- Weihua Guan
Organizations
- Alexion Pharmaceuticals
- Amgen
- Astellas Pharma (United States)
- AstraZeneca
- AstraZeneca (United States)
- Celgene
- Chiron Corporation
- Elevance Health, Inc.
- Fred Hutchinson Cancer Center
- Genzyme
- Gilead Sciences
- Health Research
- Health Resources and Services Administration
- HistoGenetics (United States)
- Incyte
- Janssen Scientific Affairs (United States)
- Leukemia & Lymphoma Society
- Medical College of Wisconsin
- Merck & Co.
- Meso Scale Diagnostics (United States)
- Miltenyi Biotec
- National Cancer Institute
- National Heart, Lung, and Blood Institute
- National Institute of Allergy and Infectious Diseases
- National Marrow Donor Program
- Office of Naval Research
- Onyx Pharmaceuticals
- Otsuka (United States)
- Otsuka Pharmaceutical
- Patient-Centered Outcomes Research Institute
- Pfizer
- Roche (United States)
- Roswell Park Comprehensive Cancer Center
- Sanofi-Aventis
- Seagen
- Spectrum Pharmaceuticals
- St. Baldrick's Foundation
- Swedish Orphan Biovitrum
- Takeda Oncology
- United States Public Health Service
- University of Minnesota